ClinicalTrials.gov
ClinicalTrials.gov Menu

BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success (BHCG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01860690
Recruitment Status : Unknown
Verified December 2012 by Meir Medical Center.
Recruitment status was:  Recruiting
First Posted : May 23, 2013
Last Update Posted : May 23, 2013
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center

November 20, 2012
May 23, 2013
May 23, 2013
November 2011
November 2013   (Final data collection date for primary outcome measure)
To measure the change of levels of "BHCG" in patients receiving Methotrexate for treatment of ectopic pregnancy in days 4, 7, and 10 post treatment [ Time Frame: the change of levels in days 4, 7, and 10 post MTX injection ]
To compeer levels of BHCG in days 4 and 7 to day 10 after injection of MTX. for Ectopic pregnancy treatment
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success
BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success
The investigators want to compeer BHCG levels after Methotrexate ( MTX). treatment for Ectopic pregnancy in days 4 and 7 after MTX. to day 10 . The hypothesis is that "BHCG" level in day 10 is the best indicator for treatment success , superior to day 4 and 7 . According to the investigators impression BHCG level rises in days 4 and 7 due to destruction of the trophoblast tissue , and only day 10 is an indicator for treatment success
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Ectopic Pregnancy
Drug: Methotrexate
50 mg / meter squer Intramuscular (IM) MTX.
Experimental: MTX , treatment outcome
patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
Intervention: Drug: Methotrexate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
Same as current
February 2014
November 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients with ectopic pregnancy
  • healthy
  • hemodynamic stable
  • first ectopic

Exclusion Criteria:

  • hemodynamic non-stable
  • abnormal liver or kidney function
  • allergy reaction to MTX
Sexes Eligible for Study: Female
18 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT01860690
BHCG1
No
Not Provided
Not Provided
Meir Medical Center
Meir Medical Center
Not Provided
Not Provided
Meir Medical Center
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP